Bicara Therapeutics (BCAX) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Structure Therapeutics (GPCR) over the past year, losing 4.1% versus a loss of 9.8%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.14 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | GPCR |
|---|---|---|
| Share price | $17.26 | $25.67 |
| Market cap | $1.14B | $1.83B |
| 1-day change | +5.12% | -3.79% |
| YTD return | +2.55% | -63.09% |
| 1-year return | -4.11% | -9.77% |
| EPS (TTM) | $-3.08 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-141.20M |
| 52-week high | $30.99 | $94.90 |
| 52-week low | $13.70 | $25.09 |
| Distance from 52-week high | -44.30% | -72.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +105.68% | +312.08% |
| Average volume | 623.17K | 965.00K |
| Shares outstanding | 66.17M | 71.31M |
| Employees | 103 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
BCAX vs GPCR FAQ
Which is bigger, Bicara Therapeutics or Structure Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or GPCR?
BCAX returned -4.11% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.